In a filing, Neurocrine Biosciences, Inc revealed its Director Norwalk Leslie V unloaded Company’s shares for reported $0.76 million on Dec 15 ’25. In the deal valued at $152.23 per share,5,000 shares were sold. As a result of this transaction, Norwalk Leslie V now holds 7,429 shares worth roughly $0.98 million.
Then, Norwalk Leslie V sold 1,190 shares, generating $184,558 in total proceeds. Upon selling the shares at $155.09, the Director now owns 6,239 shares.
Before that, Norwalk Leslie V bought 11,250 shares. Neurocrine Biosciences, Inc shares valued at $1,745,000 were divested by the Director at a price of $155.11 per share.
Morgan Stanley downgraded its Neurocrine Biosciences, Inc [NBIX] rating to an Equal-weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in late October with a ‘”a Buy”‘ rating. Truist began covering NBIX with “Buy” recommendation on July 21, 2025. Goldman started covering the stock on July 10, 2025. It rated NBIX as “a Buy”.
Price Performance Review of NBIX
On Tuesday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock fall -0.30% to $132.26. Over the last five days, the stock has lost -3.71%. Neurocrine Biosciences, Inc shares have fallen nearly -6.13% since the year began. Nevertheless, the stocks have fallen -6.75% over the past one year.
How much short interest is there in Neurocrine Biosciences, Inc?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2025-12-31, growing by 79314.0 shares to a total of 4.07 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 3.99 million shares. There was a rise of 1.95%, which implies that there is a positive sentiment for the stock.
